Perrigo announces first-to-file patent challenge

DUBLIN — Perrigo on Wednesday announced that it has filed an abbreviated new drug application with the Food and Drug Administration for desoximetasone topical spray 0.25%. The company also has notified Taro Pharmaceuticals U.S.A., the owner of the reference listed drug, of the filing.



Taro filed suit against Perrigo on July 28, claiming patent infringement. Perrigo believes it is first to file, which entitles it to a period of generic exclusivity.



"This filing highlights our continued investment in new products and dedication to bringing topicals to market. Perrigo is committed to making quality health care more affordable for consumers around the globe," said Joseph C. Papa, Perrigo's chairman, president and CEO.



Topicort is used for the treatment of plaque psoriasis in patients 18 years of age or older. The drug had annual sales of $29 million, according to Symphony Health Solutions.